Invivyd, Inc.
A biopharmaceutical company making monoclonal antibody medicines for viral diseases, Invivyd's only commercial product is PEMGARDA (pemivibart), a preventive antibody given to certain immunocompromised adults and teens at risk of COVID-19. It was founded in 2020 as Adagio Therapeutics, a spin-out of the antibody-discovery firm Adimab, and renamed Invivyd in 2022. The name hints at its mission of building antibodies that outpace fast-mutating viruses.
Sold 5.00M
Bought 2.85M
Sold 1.73M
Granted 330.0K · Sold 150.5K
Granted 198.0K · Sold 90.3K
Granted 198.0K · Sold 83.5K
Granted 198.0K · Sold 90.3K
Granted 198.0K · Sold 90.3K
Bought 50.0K
Bought 8.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Adimab, LLC10% owner · 2 transactions | -22.1% | 21.69Mas of Jan 2024 | — | — | 5.00M |
| Elia Marc +1 co-filerSee Footnote 5 · 3 transactions | — | 15.65Mas of Aug 2022 | — | 2.85M | — |
| McGuire TerranceDirector · 16 transactions | — | 15.22Mas of Dec 2024 | — | — | 1.73M |
| Andersen JillChief Legal Officer, Secretary · 6 transactions | — | 182.2K | 330.0K | — | 150.5K |
| Lee Timothy EdwardChief Commercial Officer · 6 transactions | — | 117.7K | 198.0K | — | 90.3K |
| Allen Robert D. IIIChief Scientific Officer · 6 transactions | — | 114.5K | 198.0K | — | 83.5K |
| Duke William E.Chief Financial Officer · 6 transactions | — | 107.7K | 198.0K | — | 90.3K |
| Green JulieChief Human Resources Officer · 6 transactions | — | 107.7K | 198.0K | — | 90.3K |
| McLaughlin Kevin FDirector · 1 transaction | — | 50.0K | — | 50.0K | — |
| Hering DavidChief Executive Officer, Director · 1 transaction | — | 8.0Kas of Sep 2022 | — | 8.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -4.33M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.